Plozasiran sodium (ARO-APOC3 sodium) is a siRNA targeting APOC3. Plozasiran sodium mediates RNA interference-mediated degradation and silencing of APOC3 mRNA, reducing APOC3 synthesis and expression, apoC3 protein expression, and plasma ApoC3 concentrations. Plozasiran sodium reduces fasting and non-fasting plasma triglyceride concentrations in diet-induced hypertriglyceridemia. Plozasiran sodium can be used in research on hypertriglyceridemia, mixed hyperlipidemia, and mixed dyslipidemia [1] [2] [3] [4] [5].
In Vitro, Small interfering RNA (siRNA) is a small exogenous double-stranded RNA (dsRNA) (20-25 nucleotides) that can initiate the RNA interference (RNAi) pathway. The short dsRNA unwinds, the sense strand is degraded, and the antisense strand forms the RNA-induced silencing complex (RISC) with various protein components. The antisense strand retained in RISC is specifically complementary to the target gene mRNA. Meanwhile, RISC possesses nuclease activity, which can cleave and degrade target gene mRNA, thereby inhibiting target gene expression. Incomplete complementarity leads to inhibition of mRNA translation.
References:
[1]. Ballantyne CM, et al. Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia. The New England journal of medicine. 2024 Sep 12;391(10):899-912.
[2]. Prakash TP, et al. Discovery of long-acting APOC3 siRNA for treating patients with hypertriglyceridemia. Nucleic acids research. 2025 Oct 28;53(20):gkaf1063.
[3]. Ballantyne C, et al. Plozasiran (ARO-APOC3), decreases APOC3 and triglycerides (TG) in patients with mixed dyslipidemia: MUIR final results. Atherosclerosis. 2024 Aug 1;395.
[4]. Butler AA, et al. Fructose-induced hypertriglyceridemia in rhesus macaques is attenuated with fish oil or ApoC3 RNA interference. Journal of lipid research. 2019 Apr;60(4):805-818.
[5]. Vasas S, et al. † Plozasiran (ARO-APOC3), an Investigational RNAi, Demonstrates Robust and Durable TG Reductions in Patients with Mixed Dyslipidemia, MUIR Final Results. Journal of Clinical Lipidology. 2024 Jul 1;18(4):e560.
In Vitro, Small interfering RNA (siRNA) is a small exogenous double-stranded RNA (dsRNA) (20-25 nucleotides) that can initiate the RNA interference (RNAi) pathway. The short dsRNA unwinds, the sense strand is degraded, and the antisense strand forms the RNA-induced silencing complex (RISC) with various protein components. The antisense strand retained in RISC is specifically complementary to the target gene mRNA. Meanwhile, RISC possesses nuclease activity, which can cleave and degrade target gene mRNA, thereby inhibiting target gene expression. Incomplete complementarity leads to inhibition of mRNA translation.
References:
[1]. Ballantyne CM, et al. Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia. The New England journal of medicine. 2024 Sep 12;391(10):899-912.
[2]. Prakash TP, et al. Discovery of long-acting APOC3 siRNA for treating patients with hypertriglyceridemia. Nucleic acids research. 2025 Oct 28;53(20):gkaf1063.
[3]. Ballantyne C, et al. Plozasiran (ARO-APOC3), decreases APOC3 and triglycerides (TG) in patients with mixed dyslipidemia: MUIR final results. Atherosclerosis. 2024 Aug 1;395.
[4]. Butler AA, et al. Fructose-induced hypertriglyceridemia in rhesus macaques is attenuated with fish oil or ApoC3 RNA interference. Journal of lipid research. 2019 Apr;60(4):805-818.
[5]. Vasas S, et al. † Plozasiran (ARO-APOC3), an Investigational RNAi, Demonstrates Robust and Durable TG Reductions in Patients with Mixed Dyslipidemia, MUIR Final Results. Journal of Clinical Lipidology. 2024 Jul 1;18(4):e560.